Feyi Olopade Ayodele Highlights Positive Outcomes of Genetic Screening for Cancer

Patients who adhere to a CancerIQ cancer prevention plan, or cancer survivorship plan, are more likely to catch a cancer before it grows beyond 1 centimeter, says Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.

Transcript

What are the success rates for predicting cancer risk by using genetic services?

At CancerIQ, we look at success in multiple different ways. We are not a diagnostic test ourselves. We really do rely on some of the highest quality genetic testing labs that are out there and we partner with them to make sure our providers can access best-in-class genetic testing. But when it comes to the benefits or repeatable outcomes that CancerIQ can drive, this really is our secret sauce. We’ve already found that patients that adhere to a CancerIQ cancer prevention plan, or cancer survivorship plan are more likely to catch a cancer before it grows beyond 1 centimeter.

To date, in the case study that we’re going to talk about [at the Association of Community Cancer Centers 45th Annual Meeting & Cancer Center Business Summit], you’ll see that we were able to find 3 patients who already had cancer using that breast MRI that CancerIQ recommended before it grew beyond a centimeter. They had a much higher chance of survival, less costly treatment, and we’ve demonstrated, full circle, CancerIQ’s impact on early detection.